Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 4c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.34 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• Waste stocks ride AI and healthcare boom as CLH surges 27%